Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase

Leo R. Fitzpatrick, Cecelia Green, Elizabeth Frauenhoffer, Kevin J. French, Yan Zhuang, Lynn W. Maines, John J. Upson, Emmanuel Paul, Henry Donahue, Timothy Mosher, Charles Smith

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Pro-inflammatory cytokines like TNF-α activate sphingosine kinase (SK). Therefore, inhibition of SK is a potential molecular target for the treatment of rheumatoid arthritis. Aims: The primary goal of this study was to assess the efficacy of ABC249640 (a selective SK-2 inhibitor) in two models of rodent arthritis. A secondary goal was to evaluate the pharmacological profile of ABC294640, when given in combination with methotrexate. Methods: The efficacy of ABC294640 was determined by paw diameter/volume measurements, histological evaluations, and micro-CT analyses. Results: ABC294640 attenuated both collagen-induced arthritis in mice, as well as adjuvant-induced arthritis in rats. With the adjuvant arthritis model, the prophylactic efficacy profile of ABC294640 was similar to indomethacin. Of note, ABC294640 reduced the bone and cartilage degradation, associated with adjuvant-induced arthritis. Rats treated with a suboptimal dose of MTX (50 μg/kg/day) in combination with ABC249640 (100 mg/kg/day) had better anti-arthritis effects in the adjuvant model, than treatment with either agent alone. Conclusion: Our results suggest that ABC249640 is an orally available drug candidate with a good pre-clinical efficacy profile for the prevention and/or treatment of RA.

Original languageEnglish (US)
Pages (from-to)75-87
Number of pages13
JournalInflammopharmacology
Volume19
Issue number2
DOIs
StatePublished - Apr 1 2011

Fingerprint

Experimental Arthritis
Arthritis
Rodentia
Methotrexate
Indomethacin
Cartilage
Rheumatoid Arthritis
sphingosine kinase
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
Pharmacology
Cytokines
Bone and Bones
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Immunology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Fitzpatrick, Leo R. ; Green, Cecelia ; Frauenhoffer, Elizabeth ; French, Kevin J. ; Zhuang, Yan ; Maines, Lynn W. ; Upson, John J. ; Paul, Emmanuel ; Donahue, Henry ; Mosher, Timothy ; Smith, Charles. / Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase. In: Inflammopharmacology. 2011 ; Vol. 19, No. 2. pp. 75-87.
@article{bb5f0c7792554ebe9c2f40beaaa991a4,
title = "Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase",
abstract = "Pro-inflammatory cytokines like TNF-α activate sphingosine kinase (SK). Therefore, inhibition of SK is a potential molecular target for the treatment of rheumatoid arthritis. Aims: The primary goal of this study was to assess the efficacy of ABC249640 (a selective SK-2 inhibitor) in two models of rodent arthritis. A secondary goal was to evaluate the pharmacological profile of ABC294640, when given in combination with methotrexate. Methods: The efficacy of ABC294640 was determined by paw diameter/volume measurements, histological evaluations, and micro-CT analyses. Results: ABC294640 attenuated both collagen-induced arthritis in mice, as well as adjuvant-induced arthritis in rats. With the adjuvant arthritis model, the prophylactic efficacy profile of ABC294640 was similar to indomethacin. Of note, ABC294640 reduced the bone and cartilage degradation, associated with adjuvant-induced arthritis. Rats treated with a suboptimal dose of MTX (50 μg/kg/day) in combination with ABC249640 (100 mg/kg/day) had better anti-arthritis effects in the adjuvant model, than treatment with either agent alone. Conclusion: Our results suggest that ABC249640 is an orally available drug candidate with a good pre-clinical efficacy profile for the prevention and/or treatment of RA.",
author = "Fitzpatrick, {Leo R.} and Cecelia Green and Elizabeth Frauenhoffer and French, {Kevin J.} and Yan Zhuang and Maines, {Lynn W.} and Upson, {John J.} and Emmanuel Paul and Henry Donahue and Timothy Mosher and Charles Smith",
year = "2011",
month = "4",
day = "1",
doi = "10.1007/s10787-010-0060-6",
language = "English (US)",
volume = "19",
pages = "75--87",
journal = "Inflammopharmacology",
issn = "0925-4692",
publisher = "Birkhauser Verlag Basel",
number = "2",

}

Fitzpatrick, LR, Green, C, Frauenhoffer, E, French, KJ, Zhuang, Y, Maines, LW, Upson, JJ, Paul, E, Donahue, H, Mosher, T & Smith, C 2011, 'Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase', Inflammopharmacology, vol. 19, no. 2, pp. 75-87. https://doi.org/10.1007/s10787-010-0060-6

Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase. / Fitzpatrick, Leo R.; Green, Cecelia; Frauenhoffer, Elizabeth; French, Kevin J.; Zhuang, Yan; Maines, Lynn W.; Upson, John J.; Paul, Emmanuel; Donahue, Henry; Mosher, Timothy; Smith, Charles.

In: Inflammopharmacology, Vol. 19, No. 2, 01.04.2011, p. 75-87.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase

AU - Fitzpatrick, Leo R.

AU - Green, Cecelia

AU - Frauenhoffer, Elizabeth

AU - French, Kevin J.

AU - Zhuang, Yan

AU - Maines, Lynn W.

AU - Upson, John J.

AU - Paul, Emmanuel

AU - Donahue, Henry

AU - Mosher, Timothy

AU - Smith, Charles

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Pro-inflammatory cytokines like TNF-α activate sphingosine kinase (SK). Therefore, inhibition of SK is a potential molecular target for the treatment of rheumatoid arthritis. Aims: The primary goal of this study was to assess the efficacy of ABC249640 (a selective SK-2 inhibitor) in two models of rodent arthritis. A secondary goal was to evaluate the pharmacological profile of ABC294640, when given in combination with methotrexate. Methods: The efficacy of ABC294640 was determined by paw diameter/volume measurements, histological evaluations, and micro-CT analyses. Results: ABC294640 attenuated both collagen-induced arthritis in mice, as well as adjuvant-induced arthritis in rats. With the adjuvant arthritis model, the prophylactic efficacy profile of ABC294640 was similar to indomethacin. Of note, ABC294640 reduced the bone and cartilage degradation, associated with adjuvant-induced arthritis. Rats treated with a suboptimal dose of MTX (50 μg/kg/day) in combination with ABC249640 (100 mg/kg/day) had better anti-arthritis effects in the adjuvant model, than treatment with either agent alone. Conclusion: Our results suggest that ABC249640 is an orally available drug candidate with a good pre-clinical efficacy profile for the prevention and/or treatment of RA.

AB - Pro-inflammatory cytokines like TNF-α activate sphingosine kinase (SK). Therefore, inhibition of SK is a potential molecular target for the treatment of rheumatoid arthritis. Aims: The primary goal of this study was to assess the efficacy of ABC249640 (a selective SK-2 inhibitor) in two models of rodent arthritis. A secondary goal was to evaluate the pharmacological profile of ABC294640, when given in combination with methotrexate. Methods: The efficacy of ABC294640 was determined by paw diameter/volume measurements, histological evaluations, and micro-CT analyses. Results: ABC294640 attenuated both collagen-induced arthritis in mice, as well as adjuvant-induced arthritis in rats. With the adjuvant arthritis model, the prophylactic efficacy profile of ABC294640 was similar to indomethacin. Of note, ABC294640 reduced the bone and cartilage degradation, associated with adjuvant-induced arthritis. Rats treated with a suboptimal dose of MTX (50 μg/kg/day) in combination with ABC249640 (100 mg/kg/day) had better anti-arthritis effects in the adjuvant model, than treatment with either agent alone. Conclusion: Our results suggest that ABC249640 is an orally available drug candidate with a good pre-clinical efficacy profile for the prevention and/or treatment of RA.

UR - http://www.scopus.com/inward/record.url?scp=79958190513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958190513&partnerID=8YFLogxK

U2 - 10.1007/s10787-010-0060-6

DO - 10.1007/s10787-010-0060-6

M3 - Article

C2 - 20936538

AN - SCOPUS:79958190513

VL - 19

SP - 75

EP - 87

JO - Inflammopharmacology

JF - Inflammopharmacology

SN - 0925-4692

IS - 2

ER -